title: Hemostasis activation in patients with liver cirrhosis.
abstract: In patients with liver cirrhosis a decrease of the coagulant potential is well-documented and has been linked to the high bleeding tendency among these patients. Whether the decrease of the coagulant potential is only due to a reduced hepatic synthesis of coagulation factors or also to its consumption by disseminated intravascular coagulation is debatable. We investigated hemostasis activation markers thrombin-antithrombin III complexes (TAT), fibrin degradation products (D-Dimer) and plasmin-alpha 2-antiplasmin complexes (PAP) in 41 outpatients with liver cirrhosis (Child-Pugh index 1 n = 18, 2 n = 15, 3 n = 8). Compared to controls similar in terms of age and sex, TAT, D-Dimer and PAP was elevated in the whole group of patients. A progressive increase of D-Dimer and PAP from Child 1 to 3 indicates a relationship between the severity of cirrhosis and the amount of hemostasis activation. Investigation of the natural anticoagulant potential showed significant decreases of antithrombin III (AT III), protein C, and protein S, most pronounced in Child 3 patients. Statistical analysis revealed significant negative correlations between levels of D-Dimer and both AT III and protein C, indicating that hemostasis activation is linked to the loss of anticoagulant potential.
authors.affiliation: Department of Medicine II, University of Vienna, Austria.
authors.forename: T
authors.initials: T
authors.lastname: Vukovich
authors.forename: H
authors.initials: H
authors.lastname: Teufelsbauer
authors.forename: M
authors.initials: M
authors.lastname: Fritzer
authors.forename: S
authors.initials: S
authors.lastname: Kreuzer
authors.forename: P
authors.initials: P
authors.lastname: Knoflach
mesh_terms: D000328:Adult; D000368:Aged; D000990:Antithrombin III / Q000032:analysis; D015415:Biomarkers / Q000097:blood; D001780:Blood Coagulation Tests; D001798:Blood Proteins / Q000032:analysis*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005341:Fibrinolysin / Q000032:analysis; D006474:Hemorrhagic Disorders / Q000209:etiology; D006487:Hemostasis; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood* / Q000150:complications; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000032:analysis; D011486:Protein C / Q000032:analysis; D017293:Protein S / Q000032:analysis; D000979:alpha-2-Antiplasmin / Q000032:analysis
chemical_list: D015415:Biomarkers; D001798:Blood Proteins; D005338:Fibrin Fibrinogen Degradation Products; D011486:Protein C; D017293:Protein S; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; D000990:Antithrombin III; D010447:Peptide Hydrolases; D005341:Fibrinolysin